In last trading session, Monopar Therapeutics Inc (NASDAQ:MNPR) saw 0.57 million shares changing hands with its beta currently measuring 1.02. Company’s recent per share price level of $33.6 trading at -$1.41 or -4.03% at ring of the bell on the day assigns it a market valuation of $205.47M. That closing price of MNPR’s stock is at a discount of -61.61% from its 52-week high price of $54.30 and is indicating a premium of 94.88% from its 52-week low price of $1.72. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 78770.0 shares which gives us an average trading volume of 22.63K if we extend that period to 3-months.
For Monopar Therapeutics Inc (MNPR), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.33. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Monopar Therapeutics Inc (NASDAQ:MNPR) trade information
Upright in the red during last session for losing -4.03%, in the last five days MNPR remained trading in the green while hitting it’s week-highest on Thursday, 06/26/25 when the stock touched $33.6 price level, adding 5.59% to its value on the day. Monopar Therapeutics Inc’s shares saw a change of 719.51% in year-to-date performance and have moved 2.25% in past 5-day. Monopar Therapeutics Inc (NASDAQ:MNPR) showed a performance of 3.51% in past 30-days. Number of shares sold short was 25155.0 shares which calculate 1.07 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 29.5 to the stock, which implies a fall of -13.9% to its current value. Analysts have been projecting 22 as a low price target for the stock while placing it at a high target of 37. It follows that stock’s current price would jump 34.52% in reaching the projected high whereas dropping to the targeted low would mean a gain of 34.52% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -15.56% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 49.92% while estimates for its earnings growth in next 5 years are of 20.53%.
Monopar Therapeutics Inc (NASDAQ:MNPR)’s Major holders
Insiders are in possession of 34.38% of company’s total shares while institution are holding 47.24 percent of that, with stock having share float percentage of 71.99%. Investors also watch the number of corporate investors in a company very closely, which is 47.24% institutions for Monopar Therapeutics Inc that are currently holding shares of the company. MILLENNIUM MANAGEMENT LLC is the top institutional holder at MNPR for having 0.19 million shares of worth $0.15 million. And as of 2024-06-30, it was holding 0.2432 of the company’s outstanding shares.
The second largest institutional holder is GEODE CAPITAL MANAGEMENT, LLC, which was holding about 60036.0 shares on 2024-06-30. The number of shares represents firm’s hold over 0.0751 of outstanding shares, having a total worth of $44906.0.